Coya Therapeutics, Inc. (NASDAQ:COYA) Given Consensus Rating of “Moderate Buy” by Brokerages

Coya Therapeutics, Inc. (NASDAQ:COYA) has been assigned a consensus rating of “Moderate Buy” from the six research firms that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $16.20.

Several research analysts recently weighed in on the stock. Chardan Capital reissued a “buy” rating and set a $14.00 price objective on shares of Coya Therapeutics in a research note on Wednesday, September 17th. Lake Street Capital began coverage on shares of Coya Therapeutics in a research note on Wednesday, July 9th. They issued a “buy” rating and a $16.00 price target on the stock. BTIG Research reaffirmed a “buy” rating and issued a $15.00 price target on shares of Coya Therapeutics in a research note on Tuesday, September 30th. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price target on shares of Coya Therapeutics in a research note on Monday, August 25th. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $18.00 price target on shares of Coya Therapeutics in a research note on Monday, September 29th.

Institutional Trading of Coya Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Charles Schwab Investment Management Inc. acquired a new stake in shares of Coya Therapeutics in the first quarter valued at approximately $65,000. Jane Street Group LLC raised its holdings in shares of Coya Therapeutics by 101.7% in the first quarter. Jane Street Group LLC now owns 26,137 shares of the company’s stock valued at $169,000 after purchasing an additional 13,176 shares during the last quarter. Northwestern Mutual Wealth Management Co. acquired a new stake in shares of Coya Therapeutics in the second quarter valued at approximately $119,000. CM Management LLC raised its holdings in shares of Coya Therapeutics by 25.0% in the first quarter. CM Management LLC now owns 200,000 shares of the company’s stock valued at $1,294,000 after purchasing an additional 40,000 shares during the last quarter. Finally, Dauntless Investment Group LLC acquired a new stake in shares of Coya Therapeutics in the first quarter valued at approximately $1,083,000. 39.75% of the stock is currently owned by institutional investors and hedge funds.

Coya Therapeutics Price Performance

Coya Therapeutics stock opened at $6.29 on Friday. The company’s 50 day simple moving average is $6.23 and its 200 day simple moving average is $6.04. Coya Therapeutics has a fifty-two week low of $4.65 and a fifty-two week high of $8.29. The firm has a market capitalization of $105.29 million, a price-to-earnings ratio of -5.07 and a beta of 0.19.

Coya Therapeutics (NASDAQ:COYA) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.14). The company had revenue of $0.16 million for the quarter, compared to analyst estimates of $0.78 million. As a group, analysts predict that Coya Therapeutics will post -1.15 EPS for the current fiscal year.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.